73 related articles for article (PubMed ID: 6849767)
1. Antipyrine kinetics in liver disease and liver transplantation.
Mehta MU; Venkataramanan R; Burckart GJ; Ptachcinski RJ; Yang SL; Gray JA; Van Thiel DH; Starzl TE
Clin Pharmacol Ther; 1986 Apr; 39(4):372-7. PubMed ID: 3514052
[TBL] [Abstract][Full Text] [Related]
2. Measurement of antipyrine half-life from urinary drug concentrations.
Taylor G; Blaschke TF
Br J Clin Pharmacol; 1984 Oct; 18(4):650-2. PubMed ID: 6487512
[No Abstract] [Full Text] [Related]
3. Adverse effects from metoprolol are not generally associated with oxidation status.
Clark DW; Morgan AK; Waal-Manning H
Br J Clin Pharmacol; 1984 Dec; 18(6):965-7. PubMed ID: 6335664
[No Abstract] [Full Text] [Related]
4. Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine.
Shaw PN; Houston JB; Rowland M; Hopkins K; Thiercelin JF; Morselli PL
Br J Clin Pharmacol; 1985 Dec; 20(6):611-8. PubMed ID: 4091993
[TBL] [Abstract][Full Text] [Related]
5. Polymorphism of theophylline metabolism in man.
Miller CA; Slusher LB; Vesell ES
J Clin Invest; 1985 May; 75(5):1415-25. PubMed ID: 4039734
[TBL] [Abstract][Full Text] [Related]
6. Carbamazepine metabolism in man. Induction and pharmacogenetic aspects.
Eichelbaum M; Tomson T; Tybring G; Bertilsson L
Clin Pharmacokinet; 1985; 10(1):80-90. PubMed ID: 3971637
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic differences in the inhibitory effect of cimetidine on the metabolism of antipyrine.
Gachályi B; Vas A; Csillag K; Nagy B; Kocsis F; Káldor A
Eur J Clin Pharmacol; 1987; 31(5):613-5. PubMed ID: 3830247
[TBL] [Abstract][Full Text] [Related]
8. Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine.
Eichelbaum M; Bertilsson L; Küpfer A; Steiner E; Meese CO
Br J Clin Pharmacol; 1988 Apr; 25(4):505-8. PubMed ID: 3382592
[TBL] [Abstract][Full Text] [Related]
9. Biliary excretion of antipyrine and its metabolites after cholecystectomy.
Mönig H; Wilhelmy J; John S; Ohnhaus EE
Br J Clin Pharmacol; 1988 Feb; 25(2):279-80. PubMed ID: 3358892
[No Abstract] [Full Text] [Related]
10. Benzbromarone biotransformation is not related to polymorphic oxidation of sparteine.
Walter-Sack I; Eichelbaum M; de Vries JX; Weber E
Klin Wochenschr; 1988 Nov; 66(21):1097-8. PubMed ID: 3236759
[No Abstract] [Full Text] [Related]
11. Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine.
Blyden GT; Greenblatt DJ; LeDuc BW; Scavone JM
Eur J Clin Pharmacol; 1988; 35(4):413-7. PubMed ID: 3197750
[TBL] [Abstract][Full Text] [Related]
12. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
Clark DW
Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
[TBL] [Abstract][Full Text] [Related]
13. Antipyrine metabolism is not affected by terbinafine, a new antifungal agent.
Seyffer R; Eichelbaum M; Jensen JC; Klotz U
Eur J Clin Pharmacol; 1989; 37(3):231-3. PubMed ID: 2612536
[TBL] [Abstract][Full Text] [Related]
14. Plasma antipyrine half-life can be determined from urine data.
Atiba JO; Taylor G; Pershe RA; Blaschke TF
Br J Clin Pharmacol; 1987 Jun; 23(6):715-9. PubMed ID: 2440468
[TBL] [Abstract][Full Text] [Related]
15. Variation of benzbromarone elimination in man--a population study.
Walter-Sack I; Gresser U; Adjan M; Kamilli I; Ittensohn A; de Vries JX; Weber E; Zöllner N
Eur J Clin Pharmacol; 1990; 39(2):173-6. PubMed ID: 2253669
[TBL] [Abstract][Full Text] [Related]
16. Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.
Eichelbaum M; Bertilsson L; Säwe J
Br J Clin Pharmacol; 1983 Mar; 15(3):317-21. PubMed ID: 6849767
[TBL] [Abstract][Full Text] [Related]
17. Theophylline metabolism in relation to antipyrine, debrisoquine, and sparteine metabolism.
Dahlqvist R; Bertilsson L; Birkett DJ; Eichelbaum M; Säwe J; Sjöqvist F
Clin Pharmacol Ther; 1984 Jun; 35(6):815-21. PubMed ID: 6734034
[TBL] [Abstract][Full Text] [Related]
18. Deficient metabolism of debrisoquine and sparteine.
Inaba T; Otton SV; Kalow W
Clin Pharmacol Ther; 1980 Apr; 27(4):547-9. PubMed ID: 7357813
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
